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Tacrolimus was used as the primary immunosup-
pressive agent in 69 pediatric renal transplantations 
between December 17, 1989, and June 30, 1995. Chil-
dren undergoing concomitant or prior liver and/or in-
testinal transplantation were excluded from analysis. 
The mean recipient age was 10.3:5.0 years (range, 
0.7-17.5 years). Seventeen (24.6%) children were un-
dergoing retransplantation, and six (8.7%) had a panel 
reactive antibody level of 40% or higher. Thirty-nine 
(57%) cases were with cadaveric kidneys, and 30 (43%) 
were with living donors. The mean donor age was 
28.0±14.7 years (range, 1.0-50.0 years), and the mean 
cold ischemia time for the cadaveric kidneys was 
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27.0±9.4 hr. The antigen match was 2.7±1.2, and the 
mismatch was 3.1 ± 1.2. All patients received tacroli-
mus and steroids, without antibody induction, and 
26% received azathioprine as well. The mean follow-up 
was 32±20 months. One- and 4-year actuarial patient 
survival rates were 100% and 95%. One- and 4-year 
actuarial graft survival rates were 99% and 85%. The 
mean serum creatinine level was 1.2:0.8 mgldl, and 
the calculated creatinine clearance was 82:26 mIImini 
1.73 m 2 • The mean tacrolimus dose was 0.22:0.14 mg/ 
kg/day, and the level was 9.5±4.8 nglml. The mean 
prednisone dose was 2.1±4.9 mglday (O.07±0.17 mg/kgl 
day), and 73% of successfully transplanted children 
were off prednisone. Seventy-nine percent were not 
taking any antihypertensive medications. The mean 
serum cholesterol level was 158±54 mgldl. The inci-
dence of delayed graft function was 4.3%. The inci-
dence of rejection was 49%, and the incidence of ste-
roid-resistant rejection was 6%. The incidence of 
rejection decreased to 27% in the most recent 26 cases 
<January 1994 through June 1995). The incidence of 
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n(Ow-onset diabetes was 10.1%; six ofthe seven affected 
children were able to be weaned off insulin. The inci-
dence of cytomegalovirus disease was 13%, and that of 
posttransplant Iymphoproliferative disorder was 10%; 
the incidence of posttransplant lymphoproliferative 
disorder in the last 40 transplants was 5% (two cases). 
All of the children who developed posttransplant lym-
phoproliferative disorder are alive and have function-
ing allografts. Based on this data, we believe that ta-
crolimus is a superior immunosuppressive agent in 
pediatric renal transplant patients, with excellent 
short- and medium-term patient and graft survival, an 
ability to withdraw steroids in the majority of pa-
tients, and, with more experience, a decreasing rate of 
rejection and viral complications. 
Tacrolimus is a relatively new immunosuppressive agent, 
approved by the FDA in June 1994, for use in liver transplant 
recipients (1-6). It has, however, also been used in adults 
undergoing renal transplantation, both as a primary and as 
a rescue agent, in many centers around the world (7-14). For 
the same toxicities, principally nephrotoxicity, neurotoxicity, 
and diabetogenicity (15-20), it has been shown to have more 
immunosuppressive efficacy than cyclosporine-based therapy 
(8,9,21). This has been manifested by improved short- and 
projected long-term graft survival, and an increased ability to 
wean steroids completely (8,9,21,22). 
There has been rather less experience with tacrolimus in 
pediatric renal transplantation, although the early experi-
ence has been encouraging (23-28). In this report, our cumu-
lative experience with tacrolimus as the primary immuno-
suppressive agent in pediatric renal transplant recipients is 
summarized, and the lessons we have learned and the details 
of our current strategies for using this agent are described. 
PATIENTS AND METHODS 
Between December 17, 1989, and June 30,1995, tacrolimus was 
used as a primary immunosuppressive agent in 69 renal transplan-
tations perfonned in 68 pediatric patients at the Children's Hospital 
of Pittsburgh (CHP; Table 1). Children who had undergone or were 
undergoing concomitant liver and/or intestinal transplantation were 
not included in this analysis. The mean recipient age was 10.3:t5.0 
years (range, 0.7-17.5 years). Five (7.2%) children were under 2 
years of age at the time of transplantation, and another eight (11.6%) 
were between 2 and 5 years of age. Seventeen (24.6%) children were 
undergoing retransplantation; eleven (15.9%) received their second, 
five (7.2%) received their third, and one (1.4%) received his fourth 
transplant. Nine patients had been transplanted previously else-
where, and eight had received transplants previously at CHP. Six 
(8.7%) children had a panel reactive antibody (PRA) level over 40%. 
The causes of end-stage renal disease are listed in Table 2. 
Thirty-nine (57%) transplants were with cadaveric kidneys, and 
30 (43%) were with living donors (28 parents, 1 grandmother, and 1 
adoptive father; Table 1). The mean donor age was 28.0:t14.7 years 
(range, 1.0-50.0 years). The mean cold ischemia time for the cadav-
eric kidneys was 27.0:::9.4 hr. Eight (20.5%) of the cadaveric cases 
were with donors less than 5 years of age, and of these, two were with 
pediatric en bloc kidneys from donors 1 year and 1.2 years of age. All 
of the recipients of these pediatric kidneys were over 10 years of age. 
The mean number of antigen matches and mismatches was 2.7:t 1.2 
and 3.1:!: 1.2, respectively. 
Immunosuppression was with tacrolimus (26, 27, 29); 26% of pa-
* Abbreviations: CHP, Children's Hospital of Pittsburgh; CMY, 
cytomegalovirus; PRA, panel reactive antibody; PTLD, posttrans-
plant lymphoproliferative disorder. 
TABLE 1. Recipient and donor demographics: time period 
12117/89 - 6/30/95 
No. of transplants 
No. of children 
69 
68 
Recipient age (yr) 
<2 years 
10.3:t5.0 (range, 0.7-17.5) 
5 (7.2%) 
2-5 years 
Retransplants 
2nd transplant 
3rd transplant 
4th transplant 
PRA ~4M% 
Cadaveric donors 
Living donors 
Donor age (yr) 
Cold ischemia time (hr) 
Pediatric donors s5 years 
Antigen match 
Antigen mismatch 
o Antigen mismatch 
8 (11.6%) 
17 (24.6%) 
11 (15.9%) 
5 (7.2%) 
1 (1.4%) 
6 (8.7%) 
39 (57%) 
30 (43%) 
28.0:t14.7 
27.0:t9.4 
8(20.5%) 
2.7:t1.2 
3.1:tl.2 
2 (2.9%) 
TABLE 2. Causes of end-stage renal disease 
Obstructive uropathy 
Congenital dysplasia 
Membranoproliferative glomerulonephritis 
Focal segmental glomerulosclerosis 
Hemolytic-uremic syndrome 
Polycystic kidney disease 
Prune belly 
Reflux 
Congenital hypoplasia 
Cystinosis 
Interstitial nephritis 
Other 
Unknown 
12 (17%) 
10 (14%) 
8 (12%) 
7 (10%) 
4(6%) 
3 (4%) 
3(4%) 
3(4%) 
2 (3%) 
2(3%) 
2(3%) 
9 (13%) 
4(6%) 
tients received azathioprine as well. Induction antilymphocyte ther-
apy was not used. Tacrolimus was given orally at a dose of 0.15 
mg/kg before surgery. After surgery, it was begun as a continuous 
intravenous infusion of 0.075-0.10 mglkg!day. Once patients were 
able to tolerate a diet, they were started on oral tacrolimus, 0.15 
mg/kg twice a day, and the intravenous tacrolimus was gradually 
tapered off. Plasma levels were followed initially; for the past 2 
years, whole blood IMx levels have been used. Current tacrolimus 
target levels and steroid dosing guidelines are shown in Table 3. 
Statistical analysis. The patient survival rate was calculated 
from the date of kidney transplantation until death, and the graft 
survival rate was calculated from the date of kidney transplantation 
until graft failure. retransplantation, or patient death. Survival 
curves were generated using the Kaplan-Meier (product limit) 
method and were compared using the log-rank (Mantel-Cox) test. All 
tests were two-tailed. A P-value less than 0.05 was considered sta-
tistically significant. 
Until June 1994, when tacrolimuB was approved by the U.S. Food 
and Drug Administration, all transplants were done under a protocol 
approved by the Human Rights Committee of CHP. 
RESULTS 
The mean follow-up was 32::20 months. 
The overall 1- and 4-year actuarial patient survival rates 
were 100% and 95% (Fig. 1, Table 3). Two patients died 3.3 
years and 1.3 years after transplantation. The first patient 
was a 17.4-year-old white female with end-stage renal dis-
ease secondary to ureteral reflux who lost her allograft to 
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TABLE 3. Tacrolimus target levels 
Time 
First 2 weeks 
1 month 
3 months 
Chronic 
Level (ng/ml) 
20-25 
15-20 
10-15 
<5 to &-9 
Guidelines for steroid dosing 
Time 
Intraoperative 
Postoperative day 1~ 
Weeks 2-3 
Weeks 4-5 
Weeks 6-7 
2 months 
2-112 months 
3 months 
3-112 months 
4 months 
5 months 
6 months 
(53) 
Dole (mg!kg/day) 
15-25 
3-10 -+ 0.3-1 
0.25-0.75 
0.2 to 0.5-0.6 
0.17-0.2 to 0.4--0.5 
0.17 to 0.25-0.3 
0.15 to 0.13-0.2 
0.13-0.1 
0.13-0.05 
0.0&-0 
0.05-0 
o 
100 (42) (17) 
------- ... 
----t __ , (19) 
,- -. 
--------
80 
60 
40 
20 
__ Patient Survival (n=68) 
- -
Graft Survival (n=6?) 
0 
0 6 12 18 24 30 36 42 48 
Months After Transplantation 
FIGURE 1. Kaplan-Meier patient and graft survival rates for pediat-
ric kidney transplantation from December 14, 1989, to June 30, 
1995. The number in parentheses represents the number of patients 
at risk. 
noncompliance 1.8 years after transplantation and died on 
dialysis (otT immunosuppression) 1.5 years later of uncertain 
causes. The second was a 17.5-year-old black male with sickle 
cell anemia, who had a difficult course after transplantation, 
including fungal infection (Rhizopus) of his left native kid-
ney, several episodes of rejection, and recurrent sickle crises. 
He rather suddenly developed fungal sepsis 1.3 years after 
transplantation, with a mycotic aneurysm of the superior 
mesenteric artery and associated infarction of his entire gas-
trointestinal tract. 
The overall 1- and 4-year actuarial graft survival rates 
were 99% and 85% (Fig. 1, Table 41. Eight patients lost their 
allografts. three to chronic rejection 1.1, 2.8, and 4.2 years 
after transplantation, three to recurrent disease (hemolytic-
uremic syndrome at 0.02 years, membranoproliferative glo-
merulonephritis type II at 3.4 years, and focal segmental 
glomerulosclerosis at 2.1 years), one to death at 1.3 years. 
and one to noncompliance at 1.8 years (Table 4 J. One- and 
-i-year actuarial graft survival rates in selected subgroups 
TABLE 4. Actuarial patient and graft survival rates" 
Patient 
Graft 
1 year 
100% 
99% 
4 years 
95% 
85% 
"Causes of graft loss: disease recurrence, n=3; rejection, n=3; 
infection/death, n=1; noncompliance, n=l. 
are shown in Table 5. Interestingly, cadaveric organ recipi-
ents did as well as living donor organ recipients (the numer-
ical superiority in the cadaver group at 4 years, 89% vs. 81%, 
was not statistically different; four patients in each group 
lost their kidney). Retransplant recipients were also not sta-
tistically worse than first-transplant recipients, but there 
was an increasing difference in graft survival at "years (75% 
VB. 90%). Patients with high PRA levels did significantly 
worse than patients with low PRA levels at" years (42% vs. 
93%; P=0.0003), and the 1-year outcomes were also worse 
(83% vs. 100%). Recipient age had no etTect on graft survival, 
nor did donor age. Of note, all five recipients under 2 years of 
age and seven of the eight recipients under 5 years of age had 
functioning allografts. In addition, the 1- and 4-year graft 
survival rates for the recipients of kidneys from donors 5 
years of age or younger were both 100%; one recipient did go 
on to lose his kidney to chronic rejection at 4.2 years. Rejec-
tion was also not associated with statistically worse graft 
survival, but there was a trend toward worse outcomes at 4 
years (78% vs. 97%) in patients who experienced rejection. 
The mean serum creatinine level was 1.2:t0.8 mg/dl, and 
the calculated creatinine clearance was 82:t26 ml/min/1.73 
m2 (30). The mean blood urea nitrogen level was 25:t 13 mg/dl 
(Table 6). These values were relatively stable over time (Ta-
ble 7). 
The mean tacrolimus dose was 7.8:t6.8 mg/day (0.22:t0.14 
mg/kg/day), and the mean level was 9.S±4.8 nglml (Tables 6 
and 7). The mean prednisone dose was 2.1:t4.9 mg/day 
(0.07±0.17 mg/kg/day); for children still on prednisone. it 
was 7.1:t6.8 mg/day (0.3:t0.3 mg/kg/day). Seventy-three per-
cent of children transplanted successfully were taken otT 
prednisone (Table 6). Steroids were withdrawn at a mean 
time of7.9±5.2 months after transplantation. Ten percent of 
TABLE 5. Subgroup actuarial (Kaplan-Meier) graft survival rates 
Subgroup 1 year 4 years P" 
Cadaver 97% 89% 0.804 
Living donor 100% 81% 
First transplant 100% 90% 0.114 
Retransplant 94% 75% 
PRA <40% 100% 93% 0.0002 
PRA ;:'40% 83% 42% 
Recipient age 
<2 years 100% 100% 0.807 
2-5 years 89% 89% 
>5 years 100% 84% 
Donor age (cadaver I 
:$5 years 100% 100% 0.913 
>5 years 98% 83% 
Rejection 
No 97'k 97% 0.345 
Yes 100% 78% 
• Log-rank test. 
r 
I 
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TABLE 6. Creatine, tacrolimus, and steroid levels 
Serum creatinine 
Calculated creatinine 
clearance 
Blood urea nitrogen 
Tacrolimus 
Dose 
Level 
Steroids 
Dose (all patients) 
Dose (still on prednisone) 
Off steroids 
1.2:!:0.8 mg/dl 
82:!:26 mllminl1. 73 2 
25:!:13 mg/dl 
7.8:!:6.8 mg/day 
(0.22:!:0.14 mg/kg/day) 
9.5:!:4.8 ng/ml 
2.1:!:4.9 mg/day 
(0.07:!:0.17 mg/kg/day) 
7.1:!:6.8 mg/day 
(0.30:!:0.30 mglkglday) 
73% 
patients had to have steroids restarted. Serum creatinine 
was comparable among patients taken off steroids (1.0::tO.4 
mgldl), patients restarted on steroids (1.l::tO.7 mg/dl), and 
patients who were never taken off steroids (1.4::tOA mg/dl). 
Delayed graft function was seen in three (4.3%) patients 
(Table 8); two required dialysis. All of the delayed graft 
function was seen in cadaveric cases. 
Rejection was seen in 34 (49%) patients, and was biopsy 
proven in over 90% of the cases (Table 8). Over 90% of 
rejection episodes were seen within the first 2 weeks after 
transplantation. Steroid-resistant rejection was seen in four 
(6%) patients; 88% of the rejection episodes were treated with 
steroids and modification of the tacrolimus dosage. There 
was a decrease over time in the incidence of rejection; be-
tween December 1989 and December 1993, rejection was 
noted in 63% (27/43) of the patients; between January 1994 
and June 1995, the incidence was 27% (7/26; P=0.004). This 
was probably related to maintaining higher tacrolimus levels 
during the first 2 weeks after transplantation in the more 
recently transplanted patients (see Discussion). 
New-onset diabetes was observed in seven (10.1%) patients 
(Table 8). This was a temporary complication in six children, 
and normoglycemia off insulin was achieved within several 
months after gradually reducing both the tacrolimus and 
steroid dosages. The one patient who remained insulin de-
pendent was the sickle cell patient described above, who had 
several rejection episodes and required high doses of both 
tscrolimus and steroids. 
Cytomegalovirus (CMV), either asymptomatic infection or 
symptomatic disease, was observed in nine (13.0%) children 
(Table 6); in all of these cases, the recipients were seronega-
tive and received kidneys from seropositive donors. All pa-
tients received routine prophylaxis with high-dose oral acy-
clovir; in addition, intravenous ganciclovir and CMV 
hyperimmune globulin was given to the seropositive donor/ 
seronegative recipient cases. All affected children responded 
promptly to intravenous ganciclovir and reduction of immu-
nosuppression. In a few cases, it was possible to diagnose 
CMV infection by antigenemia testing t31l, before symptom-
atic disease developed. and treat preemptively with ganciclo-
vir. 
Early t4-6 months after transplantation) Epstein-Barr 
virus-related posttransplant lymphoproliferative disorder 
(PTLDl was seen in seven tlO.l'7cl patients (Table 8). PTLD 
was seen in the liver. gastrointestinal tract, and/or allograft. 
These cases behaved much like viral infections: all disap-
peared with cessation of immunosuppression and intrave-
nous ganciclovir. Immunosuppression was eventually rein-
troduced, and none of the children died or lost their allograft. 
Of note, the incidence of PI'LD seemed to decrease as more 
experience was acquired with tacrolimus. From December 
1989 to December 1992, five (17%) cases ofPTLD were seen, 
whereas from January 1993 until June 1995, two (5%) cases 
were reported. This was probably related both to more ag-
gressive tapering of immunosuppression beginning 6-8 
weeks after transplantation and, more recently, monitoring 
of the Epstein-Barr virus antigenemia to allow for reduction 
of immunosuppression and preemptive treatment with gan-
ciclovir before PTLD could develop. 
In addition, there was one late case of Burkitt's lymphoma 
in a 1l.8-year-old boy, which developed 3.8 years after trans-
plantation and 3 months after his maintenance immunosup-
pression was increased by 50%. This patient received chemo-
therapy with cyclophosphamide, vincristine, methotrexate, 
adriamycin, etoposide, cytosine arabinoside, and prednisone, 
which was successful in eradicating the lymphoma. His allo-
graft function remains good (serum creatinine, 1.3 mg/dl), 
and he was recently restarted on tacrolimus, at 1 mg p.o. q.d. 
Finally, there was a late case ofnon-Burkitt's lymphoma in 
a 16A-year-old boy who received a transplant in Pittsburgh 
but was followed elsewhere, which was diagnosed 4.3 years 
after transplantation. The patient was begun on a chemo-
therapy regimen identical to that described above and, in 
addition, he received local radiation therapy to the brain 
stem. Immunosuppression was discontinued, and renal func-
tion has remained normal (serum creatinine, 1.1 mgldl). 
At most recent follow-up, 79% of children with successful 
transplants were not taking antihypertensive medications. 
The mean serum cholesterol level was 158::t54 mgldl (Ta-
ble 9). 
Serial heights were reported in all children and were con-
verted to Z-scores. The mean Z-scores were plotted over time 
for all children and were stratified based on age (under 12 
years vs. 12 and over) and steroid dosage (off steroids vs. on) 
(Figs. 2 and 3 and Table 10). There was enormous variability 
in growth after transplantation. Clearly, however. children 
off steroids tended to have more accelerated growth than 
children on steroids, and children 12 years of age or younger 
at the time of transplantation tended to achieve better 
growth than children who received transplants after the age 
of 12. The most recent Z-score for children 12 and under off 
steroids was -0.94:!: 1.37; for the five children under 2 years 
of age (all of whom were off steroids), it was -0.15:!:0.77. 
DISCUSSION 
Tacrolimus has emerged as an efficacious immunosuppres-
sive agent in a wide variety of transplant settings (4-6. 
32-37). In our pediatric renal transplant recipients, it has 
been associated with excellent patient and graft survival and 
an ability to wean steroids and antihypertensive agents in 
73% and 79%, respectively, of children with successful trans-
plants. Growth. particularly in preadolescent children who 
have been weaned off steroids, has improved substantially 
and has become normal in many cases. The two major com-
plications that had been seen early in our experience with 
this agent, a moderately high incidence of rejection on the 
one hand and an alarming incidence of PTLD on the other. 
seem to have decreased over time. In the 18-month period 
-" 
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TABLE 7. Creatine, tacrolimus, and steroid values over time 
Serum creatinine (mg/dl) 
Creatinine clearance (ml/minl1. 73 m2) 
Blood urea nitrogen (mg/dl) 
Tacrolimus dose 
mg/day 
mglkg/day 
Tacrolimus levels (ng/mI) 
Prednisone dose 
All patients 
mg/day 
mglkglday 
Still on prednisone 
mglday 
.. mglkglday i~K ; ! 
... 
TABLE 8. Complications 
Delayed graft function 4.3% 
Dialysis 3% 
Rejection 49% 
Dec 1989 to Dec 1993 63% 
Jan 1994 to June 1995 27% 
Steroid-resistant rejection 6% 
New-onset diabetes 
Initial 10.1% 
Final 1.4% 
Cytomegalovirus 13.0% 
PTLD 10.1% 
Dec 1989 to Dec 1992 17% 
Jan 1993 to June 1995 5% 
Lymphoma 2.9% 
a P=0.004. 
TABLE 9. Follow-up data 
Off antihypertensive medications 
Serum cholesterol (mg/dl) 
6 months 
1.1±0.6 
81:t35 
26±11 
8.5±5.8 
0.32±0.18 
10.5±3.0 
3.3±4.4 
0.11±.14 
6.2±4.2 
·0.19±0.14 
(3169) 
(2169) 
(34169) 
(27/43)" 
(7126) 
(4169) 
(7/69) 
(1169) 
(9/69) 
(7/69) 
(5129) 
(2140) 
(2169) 
79% (48/61) 
158±54 
from January 1994 to June 1995, the incidence of rejection 
was 27% (7 of 26 cases), in contrast to the 63% (27 of 43 cases) 
incidence seen from December 1989 to December 1993. Sim-
ilarly, in the last 40 cases, PTLD was seen in two (5%) 
patients, in contrast to the five (17%) cases seen in the first 
29 patients. Although this is reassuring, the occurrence of 
two late lymphomas is of concern, and points to the need for 
continued surveillance and the importance of maintaining 
low levels of chronic immunosuppression. 
Our current practice calls for patients to receive an oral 
dose oftacrolimus, 0.15 mg/kg, on call to the operating room. 
On arrival to the intensive care unit after surgery (all of our 
children go to the intensive care unit after renal transplan-
tation). intravenous tacrolimus is started at a dose of 0.075-
0.10 mg/kg/day, as a continuous infusion. When patients are 
able to tolerate a diet, they are gradually converted to oral 
tacrolimus. starting at 0.15 mg/kg p.o. twice a day. Intrave-
nous tacrolimus is not stopped abruptly, but is tapered over 
several days. The goal is to maintain whole blood IMx levels 
of 20-25 ng/ml for the first 2 weeks after surgery. It is our 
impression that maintaining these high target trough levels 
has been important in reducing the incidence of early rejec-
tion. Tacrolimus dosages are then gradually weaned to main-
1 year 
1.0±0.4 
83±23 
24±9 
7.2±6.9 
0.23±0.11 
8.8±2.4 
1.3±3.2 
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0.20±0.11 
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2 years 
1.1±0.5 
80±25 
23±9 
6.2±3.3 
0.24±0.13 
8.7±1.9 
2.1±5.1 
0.07±0.18 
9.1±7.1 
0.30±0.28 
--Overall 
On Prednisone 
Off Prednisone 
3 years 
1.3±0.7 
79±26 
25±14 
6.7±3.6 
0.23±0.13 
7.7±2.0 
2.2±4.2 
0.07±0.14 
7.2±4.6 
0.23±O.17 
4 years 
1.4±1.0 
75±30 
26±16 
7.8±2.7 
0.26±0.11 
8.0±1.1 
3.4±5.0 
0.12±0.22 
7.9±4.7 
0.29±0.27 
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FIGURE 2. Plot of Z-scores over time fol' patients on and off steroids. 
TABLE 10. Z-score (most recent) 
<2 
2-5 
>5 
Age (yr) 
:$12, off steroids 
:$12, on steroids 
> 12, off steroids 
> 12, on steroids 
Z'8core 
-0.15:t0.77 
-1.77±0.99 
-1.47±1.60 
-0.94±1.37 
-1.84±1.70 
-1.81±1.58 
-2.08±1.46 
tain levels of 15-20 ng/ml by 1 month, 10-15 ng/ml by 3 
months, and less than 5 to 8-9 ng/ml chronically (Table 3). 
Steroids are begun in the operating room with a bolus of 
intravenous methylprednisolone, 15-25 mglkg. A short ste-
roid recycle is then given during their first postoperative 
week, tapering from 3-10 mglkg/day to 0.3-1 mglkg/day. The 
wide variability reflects a somewhat higher mglkg dosage in 
very small children. In the uncomplicated case, steroid ta-
pering is begun 2-3 weeks after surgery, with the goal of 
discontinuing steroids altogether by 4-8 months after trans-
plantation. Obviously, the tapering schedule is subject to 
modification in children experiencing rejection. Whenever 
possible. however. a consciously aggressive approach to re-
P 
[J/"N.mber 27. 1996 SHAPIRO ET AL. 1757 
-0.8 
• 1.0 
.1.2 
·IA 
'-' 
.1.6 
!:: 
ij 
-1.8 :r. 
~ 
·2.0 
·2.2 
-2.4 
-2.6 
Age<= 12 years 
Age> 12 years 
.-.-' 
.-.-.-
.-.-' 
..... -... -K-II-~-- -_ .......... -:-... -D:KK:~-- .. --_ .................. -_ .... -- .. -- -_ .. 
.' . 
.' . 
10 12 14 16 18 20 
Months After Transplantation 
FIGURE 3. Plot of Z-scores over time for patients 12 years and 
younger vs. patients older than 12 years at the time of transplanta-
tion. 
ducing immunosuppression, beginning 6-8 weeks after sur-
gery, has, in our view, been instrumental in decreasing the 
incidence of PTLD. Finally, once steroids have been discon-
tinued and a chronic maintenance dose and level of tacroli-
mus have been achieved, in the presence of stable renal 
function, the tacrolimus dose generally should not be ad-
justed upward (it may, however, need to be decreased to the 
lowest possible dosage consistent ~th avoiding rejection). 
Children do not "outgrow" their tacrolimus dosage, and the 
consequences of an unindicated increase in the dose can be 
disastrous. In practice, several pediatric patients have been 
maintained oft'steroids with tacrolimus levels of less than 5 
ng/ml (which generally means a level of 3.0-4.9 ng/ml), with 
stable, normal renal function. 
Given the excellent patient and graft survival rates ob-
tained under tacrolimus-based immunosuppression, the abil-
ity to wean steroids and antihypertensive agents in a high 
percentage of cases, and the decreasing incidence of both 
rejection and PTLD as more experience with the agent has 
been acquired, we believe that tacrolimus is the immunosup-
pressive drug of choice in children undergoing renal trans-
plantation. 
Acknowledgments. We thank Regina Fenton, RN, BSN, Loraine 
Kaminski, RN, BSN, Jennifer Ovesney, RN, M.J. Grosso, RN, MSN, 
Deborah Good, RN, BSN, Holly Woods, RN, Jareen Flohr, RN, BSN, 
Sue Bauder, RN, Sharon Orlofske, RN, and Mark Paynter, RN, BSN, 
for their help with patient care; Janet Schmelzer for her help with 
data entry and organization; Kate Carr for her help with slide 
preparation; and Susan Shandor for her help with typing the manu-
sCript and with table and slide preparation. 
REFERENCES 
1. Starzl TE. Todo S, Fung J. et al. FK506 for human liver, kidney, 
and pancreas transplantation. Lancet 1989; 2: 1000. 
2. Todo S. Fung JJ, Starzl TE. Liver. kidney, and thoracic organ 
transplantation under FK506. Ann Surg 1990; 212: 295. 
3. Fung JJ, Abu-Elmagd K. Jain A, et al. A randomized trial of 
primary liver transplantation under immunosuppression with 
FK506 vs. cyclosporine. Transplant Proc 1991; 23(6): 2977. 
4. Todo S, Fung JJ, Starzl TE, et al. Single-center experience with 
primary orthotopic liver transplantation under FK506 immu-
nosuppression. Ann Surg 1994; 220: 297 . 
5. European FK506 Multicentre Liver Study Group. Randomised 
trial comparing tacrolimus (FK506J and cyclosporin in preven-
tion of liver allograft rejection. Lancet 1994; 344: 423. 
6. U.S. Multicenter FK506 Liver Study Group. A comparison of 
tacrolimus (FK506) and cyclosporine for immunosuppression 
in liver transplantation. N Engl J Med 1994; 331: 1110. 
7. Starzl TE, Fung JJ, Jordan M, et al. Kidney transplantation 
under FK506. JAMA 1990; 264: 63. 
8. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, 
randomized trial of FK506-based immunosuppression after 
renal transplantation. Transplantation 1995; 59: 485. 
9. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, 
randomized trial of FK506lprednisone vs FK506/azathioprinei 
prednisone in renal transplant patients. Transplant Proc 1995; 
27(1): 814. 
10. Jordan M, Shapiro R, Vivas C, et al. FK506 rescue for resistant 
rejection of renal allografts under primary cyclosporine immu-
nosuppression. Transplantation 1994; 57(6): 860. 
11. Laskow DA, Vincenti F, Neylan J, Mendez R, Matas A. Phase II 
FK506 multicenter concentration control study. One-year fol-
low-up. Transplant Proc 1995; 27(1): 809. 
12. Japanese FK506 Study Group. Japanese study of FK506 on 
kidney transplantation: results of late phase II study. trans-
plant Proc 1993; 25 (1 Pt 1): 649. 
13. Ochiai T, Ishibashi M, Fukao K. et al. Japanese multicenter 
studies of FK506 in renal transplantation. Transplant Proc 
1995; 27(1): 50. 
14. Schleibner S, Kraus M, Wagner K, et aI. FK 506 versus cyclo-
sporin in the prevention of renal allograft rejection-European 
pilot study: six-week results. Transpl Int 1995; 8: 86. 
15. Demetris AJ, Banner B, Fung JJ, Shapiro R, Jordan M, Starzl 
TE. Histopathology of human renal allograft function under 
FK506: a comparison with cyclosporine. Transplant Proc 1991; 
23 (1 Pt 2): 944. 
16. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ. 
The histopathological changes associated with allograft rejec-
tion and drug toxicity in renal transplant recipients main-
tained on FK506: clinical significance and comparison with 
cyclosporine. Am J Surg Pathol 1993; 17(1): 60. 
17. Shapiro R, Fung JJ, Jain A, Parks P, Todo S, Starzl TE. The side 
effects of FK 506 in humans. Transplant Proc 1990; 22: 35. 
18. ScantleburyV, Shapiro R, FungJ, et al. New onset of diabetes in 
FK 506 versus cyclosporine-treated kidney transplant recipi-
ents. Transplant Proc 1991; 23(6): 3169. 
19. Yoshimura N, Nakai I, Ohmori Y, et al. Effect of cyclosporine on 
the endocrine and exocrine pancreas in kidney transplant re-
cipients. Am J Kidney Dis 1988; 12: 11. 
20. Boudreaux J, McHugh L, Canafax D, et al. The impact of cycle-
sporine and combination immunosuppression on the incidence 
of posttransplant diabetes in renal allograft recipients. trans-
plantation 1987; 44: 376. 
21. Gjertson DW, Cecka JM, Terasaki PI. The relative effects of 
FK506 and cyclosporine on short- and long-term kidney graft 
survival. Transplantation 1995; 60(12): 1384. 
22. Shapiro R, Jordan ML, Scantlebury VP, et al. Tacrolimus in 
renal transplantation. Transplant Proc 1996; 28(4): 2117. 
23. Starzl TE. Pediatric renal transplantation under FK506 immu-
nosuppression. Transplant Proc 1991; 23: 3075. 
24. Schneck F, Jordan M, Jensen C, et al. Pediatric renal transplan-
tation under FK506 immunosuppression. J Urol 1992; 147: 
1585. 
25. Ellis D, Shapiro R, Jordan ML, et al. Comparison of FK506 and 
cyclosporine regimens in pediatric renal transplantation. Pe-
diatr Nephrol 1994; 8: 193. 
26. Scantlebury V, Shapiro R. Tzakis A, et al. Pediatric kidney 
transplantation at the University of Pittsburgh. Transplant 
-1758 TRANSPLANTATION Vol. 62, No. 12 
Proc 1994; 26(1): 46. 
27. Shapiro R, Tzakis A, Scantlebury V, et al. Improving results of 
pediatric kidney transplantation. J Am ColI Surg 1994; 179(4): 
424. 
28. Shapiro R, Scantlebury V, Jordan ML, et al. FK506 in pediatric 
kidney transplantation-primary and rescue experience. Pedi-
atr Nephrol 1995; 9: S43. 
29. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, 
randomized trial of FK506 in renal transplantation-a com-
parison between double and triple drug therapy. Clin Trans-
plant 1994; 8: 508. 
30. Schwartz GJ, Gauthier B. A simple estimate of glomerular fil-
tration rate in adolescent boys. J Pediatr 1985; 106: 522. 
31. Grossi P, Kume S, Rinaldo C, et al. Guidance of gancic10vir 
therapy with pp65 antigenemia in cmv-free recipients of livers 
from seropositive donora. Transplantation 1996; 61: 1859. 
32. Armitage JM, Kormos RL, Fung J, Starzl TE. The clinical trial of 
FK506 as primary and rescue immunosuppression in adult 
cardiac transplantation. Transplant Proc 1991; 23(6): 3054. 
0041-1337/96/6212-1758$03.00/0 
TRANSPLANTATION 
Copyright © 1996 by Williams & Wilkins 
33. Griffith BP, Bando K, Hardesty RL, et al. A prospective random-
ized trial of FK506 versus cyclosporine after human pulmo-
nary transplantation. Transplantation 1994; 57(6): 848. 
34. Todo S, Tzakis A, Reyes J, et al. Small intestinal transplantation 
in humans with or without the colon. Transplantation 1994; 
57(6): 840. 
35. Tzakis AG, Abu-Elmagd K, Fung JJ, et al. FK506 rescue in 
chronic graft versus host disease after bone marrow transplan-
tation. Transplant Proc 1991; 23(6): 3225. 
36. Masaoka T, Shibata H, Kakishita E, Kanamaru A, Takemoto Y, 
Moriyama Y. Phase II study of FK506 for allogeneic bone 
marrow transplantation. Transplant Proc 1991; 23(6): 3228. 
37. Tzakis AG, Ricordi C, Alejandro R, et al. Pancreatic islet trans-
plantation after upper abdominal exenteration and liver re-
placement. Lancet 1990; 336: 402. 
Received 25 April 1996. 
Accepted 13 September 1996. 
Vol. 62, 1758-1762, No. 12, December 27, 1996 
PrinUd in U.S.A 
CLINICAL HEPATITIS AFTER TRANSPLANTATION OF HEPATITIS 
C VIRUS-POSITIVE KIDNEYS 
HLA-DR3 AS A RISK FACTOR FOR THE DEVELOPMENT OF POSTTRANSPLANT HEPATITIS1 
ALLAN D. KrRK,2 DENNIS M. HEISEY, ANTHONY M. D'ALESSANDRO, STUART J. KNECHTLE, 
JON S. ODORICO, STEPHEN C. RAYHILL, HANs W. SOLLINGER, AND JOlIN D. PIRSCH 
Department of Surgery, Division of Transplantation, University of Wisconsin School of Medicine, 
Madison, Wisconsin 53792 
Background. Exposure to hepatitis C virus (HCY) 
and subsequent infection after renal transplantation 
lead to significant clinical hepatitis in approximately 
50% of graft recipients. 
Methods. One hundred thirty-two consecutive renal 
allotransplant patients, who underwent transplanta-
tion of kidneys from HCV·positive cadaveric donors, 
were studied to investigate the relationship between 
donor and recipient lILA type and the risk of develop· 
ing clinical hepatitis. Specific attention was directed 
toward the DR3 and DR4 alleles, as these had previ-
ously been associated with worse prognoses in auto-
immune and viral hepatitis. 
Results. Overall, 42% of patients receiving kidneys 
from donors seropositive for HCV developed clinical 
hepatitis. This was unrelated to preoperative recipi-
ent HCV serum reactivity (P=O.65). Patients receiving 
kidneys from seropositive donors with HCV RNA as 
detected by PCR were more likely to develop hepatitis 
than those receiving kidneys from PCR-negative do-
l Presented at the 15th Annual Meeting of the American Society of 
Transplant Physicians, May 26-30, Dallas, Texas. 
2 Address correspondence to Allan D. Kirk, M.D .. Ph.D., Division 
of Transplantation. H4I710 Clinical Science Center. University of 
Wisconsin Hospital and Clinics. 600 Highland Avenue. Madison. WI 
53792 
nors (56% vs. 11%; P=O.005). The presence of the DR3 
allele was associated with a significant risk of clinical 
hepatitis (P=O.025); 80% of DR3-positive recipients 
(n=34) progressed to hepatitis compared with 42% of 
DR3-negative patients. No other recipient HLA type 
was significantly related to prognosis. All patients re-
ceiving a donated kidney that expressed the B41 allele 
developed hepatitis, compared with 55% of recipients 
of non-B41 grafts (P=O.039). No association between 
the development of clinical hepatitis and HLA compat-
ibility was found. 
Conclusions. These results suggest that both HLA 
type and viral presence as assayed by polymerase 
chain reaction, influence the risk of disease progres-
sion after transplantation of HCV-positive kidneys. 
Application of these associations may decrease the 
relative risk of a recipient contracting HCV hepatitis 
after cadaveric renal transplantation. 
Kidneys from donors infected by the hepatitis C virus 
(HCV*) have been shown to function after allotransplanta-
tion as well as kidneys from noninfected donors. Their use 
has increased the sparse supply of donor organs and has 
* Abbreviations: HBV. hepatitis B virus: HCV, hepatitis C virus: 
PCR. polymerase chain reaction. 
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